Open Access

Partial protection against collagen antibody-induced arthritis in PARP-1 deficient mice

  • Samuel García1,
  • Ana Bodaño1,
  • Antonio González1,
  • Jerónimo Forteza2,
  • Juan J Gómez-Reino3 and
  • Carmen Conde1Email author
Arthritis Research & Therapy20058:R14

https://doi.org/10.1186/ar1865

Received: 18 February 2005

Accepted: 9 November 2005

Published: 6 December 2005

Abstract

Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear DNA-binding protein that participates in the regulation of DNA repair and maintenance of genomic integrity. In addition, PARP-1 has a role in several models of inflammation disease, where its absence or inactivation confers protection. The aim of this study was to analyze the impact of selective PARP-1 suppression in collagen antibody-induced arthritis. We show that PARP-1 deficiency partially reduces the severity of arthritis, although the incidence of disease was similar in control and deficient mice. Decreased clinical scores were accompanied by partial reduction of histopathological findings. Interestingly, quantitative real-time PCR and ELISA analysis revealed that the absence of PARP-1 down-regulated IL-1β and monocyte chemotactic protein 1 expression in arthritic joints whereas tumor necrosis factor-α transcription was not impaired. Our results provide evidence of the contribution of PARP-1 to the progression of arthritis and identify this protein as a potential therapeutic target for the treatment of rheumatoid arthritis.

Introduction

Rheumatoid arthritis (RA) is characterized by inflammation, synovial hyperplasia, pannus formation and progressive destruction of cartilage and bone [1, 2]. In RA, inflammatory cytokines, chemokines, growth factors and adhesion molecules are produced by leukocytes and resident synoviocytes. These factors perpetuate chronic inflammation by the recruitment of additional inflammatory cells into the sublining region that, in turn, lead to continuous production of inflammatory mediators and enzymes, resulting in destruction of joint structures [38]. The efficacy of treatments with tumor necrosis factor (TNF) and IL-1 inhibitors strongly support the key role of inflammatory cytokines in the pathogenesis of RA [9, 10] and points to therapeutic approaches directed toward regulation of cytokine networks involved in RA.

Poly(ADP-ribose) polymerase (PARP)-1 is a highly conserved nuclear zinc-finger protein involved in maintenance of genomic integrity. PARP-1 detects DNA breakage generated by several genotoxic agents and synthesizes and transfers ADP ribose units (poly(ADPribosyl)ation activity) into acceptor proteins involved in the conservation of chromatin structure and DNA metabolism, modulating in this way DNA repair and cell survival [11, 12]. Studies with PARP-1 deficient mice or with chemical inhibitors have enlarged the physiological role of this protein. In these situations, lack of PARP-1 function protects against several disorders with an inflammatory component, such as endotoxic shock [13], streptozotocin induced diabetes [14], chronic colitis [15] and uveitis [16]. Two mechanisms have been proposed to explain the role of PARP-1 in these diseases. One mechanism is related to massive PARP-1 activation induced by genotoxic injury developed during the inflammatory process. In this case, hyperactivated PARP-1 would lead to ATP depletion and cell dysfunction [17]. The other proposed mechanism is related to a functional link between PARP-1 and inflammation-related transcription factors. Several in vivo and in vitro studies have demonstrated the involvement of PARP-1 in the transcriptional activation of nuclear factor (NF)κB [13, 18, 19], but the proposed mechanisms are contradictory. There is evidence for mechanisms that are both dependent on and independent of auto-poly(ADP-ribosyl)ation function. In the first case, NFκB would be blocked by binding to PARP-1 and this union would be disrupted by PARP-1 auto-poly(ADP-ribosyl)ation [18]. In the second case, PARP-1 would act as a transcriptional co-activator in the binding of NFκB with its target DNA sequences [19]. Recently, it has also been reported that PARP-1 regulates other transcription factors implicated in stress/inflammation, such as AP-1, Oct-1, SP-1, YY-1 and Stat-1 [20, 21]. Thus, in addition to its involvement in genome surveillance, PARP-1 appears to have a key role in inflammatory responses.

Here we report the impact of selective PARP-1 suppression on the collagen antibody-induced arthritis model (CAIA). This model, induced by passive immunization of mice with anti-type II collagen antibodies, allows the study of the effector phase of arthritis, where PARP-1 might be involved. We have found that the absence of PARP-1 partially reduced the severity of arthritis, likely by the impairment of IL-1β and monocyte chemotactic protein (MCP)-1 transcription in arthritic tissue. These results provide support for the contribution of PARP-1 in the progression of arthritis and open the possibility that specific inhibitors might become therapeutic tools in RA.

Materials and methods

Mice

Mice lacking PARP-1 (kindly provided by G de Murcia, CNRS, Strasbourg, France) have been described previously [22]. The mice used in these experiments were of mixed (C57BL/6 × 129Sv) background. More than ten different breeding pairs of parp-1+/o mice were intercrossed to generate parp-1+/+, parp-1+/o and parp-1o/o mice. Parp-1o/o mice and control matched littermates (parp-1+/+, parp-1+/o) were analyzed.

Genotypes were assessed by PCR of tail DNA. The mice were maintained in the mouse facility of the Facultad de Medicina de Santiago de Compostela. Animal care was in compliance with Spanish regulations on the protection of animals used for experimental and other scientific purposes (Real Decreto 223/1998). The experimental protocols were approved by the Animal Care and Use Committee of the University of Santiago de Compostela.

Collagen antibody-induced arthritis (CAIA) and clinical scoring

CAIA was induced in 6-week-old male and female mice by intravenous injection on day 0 of 3 mg/mouse of an arthritogenic cocktail of 4 monoclonal anti-type II collagen antibodies (Arthrogen, Chondrex, Redmond, WA, USA) [23]. On day 2, mice were boosted with 50 μg of lipopolysaccharide by intraperitoneal injection. Arthritis was assessed every other day by two blinded observers until day 12, using a semi-quantitative clinical score ranging from 0 to 4: 0, no swelling; 1, slight swelling and erythema of the ankle, wrist or digits; 2, moderate swelling and erythema; 3, severe swelling and erythema; and 4, maximal inflammation with joint rigidity. The maximum possible score was 16 per mouse.

Histological analysis

Hind limbs were prepared for histology by dissecting the skin and muscle, and then sectioning knee joints. Specimens were fixed for 24 hours and demineralized in phosphate-buffered saline-0.5 M EDTA for 10 days. Knee joints were embedded in paraffin and sections were cut and stained with hematoxylin and eosin (H&E) for evaluation of inflammation. For analysis of damage to cartilage, knee sections were stained with Toluidine blue, Safranin-O and Masson trichrome following standard methodology. The sections were scored by two blinded observers. Synovial inflammation was scored on a scale of 0 to 3: 0, no inflammation; 1, slight thickening of synovial cell layer and/or some inflammatory cells in the sublining; 2, thickening of synovial lining, infiltration of the sublining; and 3, pannus formation.

Exudate was scored according to the following scale: 0, no detectable neutrophil infiltration in the synovial space; 1, mild infiltration; 2, moderate infiltration; and 3, severe infiltration.

Cartilage damage was evaluated following a scale of 0 to 3: 0, normal cartilage; 1, cartilage surface irregularities and loss of metachromasia adjacent to superficial chondrocytes; 2, fibrillation of cartilage and formation of some chondrocyte clusters, with minor loss of surface cartilage; and 3, gross cartilage abnormalities, including loss of superficial cartilage, extension of fissures close to subchondral bone, and a large number of chondrocyte clusters.

Fibroblast like synoviocytes

Fibroblast-like synoviocytes (FLSs) were isolated from parp-1+/+, parp-1+/o and parp-1o/o mice. Synovial tissue was minced and incubated with 1 mg/ml collagenase in serum-free DMEM (Gibco, Invitrogen, Barcelona, Spain) for 3 hours at 37°C. After digestion, FLSs were filtered trough a nylon cell strainer (BD Falcon, Franklin Lakes, NJ, USA), washed extensively, and cultured in DMEM supplemented with 10% v/v FCS (Gibco, Invitrogen), penicillin, streptomycin, and L-glutamine (Sigma, St Louis, MO, USA) in a humidified 5% CO2 atmosphere. After overnight culture, non-adherent cells were removed, and adherent cells were cultured in DMEM supplemented with 10% v/v FCS.

Western blot analysis

Total proteins (20 μg) were separated by 10% SDS-PAGE, transferred to a PVDF membrane (Hybond-P, Amersham Biosciences, Buckinghamshire, UK) and probed with anti-PARP-1 (VIC-5, kindly provided by G de Murcia, CNRS, Strasbourg, France) and anti-actin (Sigma) antibodies as previously described [24]. Bound antibody was revealed with goat anti-rabbit-horseradish peroxidase (Rockland Immunochemicals Inc., Gilbertsville, PA, USA) and the blot was developed using the ECL plus detection system (Amersham Biosciences).

Quantitative reverse transcription-PCR

Total RNA was obtained from joints of parp-1+/+ and parp-1o/o mice on day 7 following Arthrogen injection, and from joints of parp-1+/+ and parp-1o/o control mice without arthritis. We used the RNeasy Kit and RNase-Free DNase Set (Qiagen GmbH, Hilden, Germany) according to the manufacturer's instructions. One microgram of total RNA was subjected to cDNA synthesis using M-MLV reverse transcriptase, random primers and RNaseOUT recombinant ribonuclease inhibitor (Invitrogen). Quantitative real-time PCR was performed in duplicate in a Chromo-4 real-time thermal cycler (MJ Research, Waltham, MA, USA), using a LightCycler DNA Master SYBR Green I kit (Roche Diagnostics, Barcelona, Spain), according to the manufacturers' protocols. The specific primers used in these reactions are listed in Table 1. Relative levels of gene expression were normalized to the β-actin gene using the comparative Ct method, where Ct is the cycle at which the amplification is initially detected. The relative amount of mRNA from the different genes was calculated using the formula 2-ΔΔCt, where:
Table 1

Primer sets used for quantitative PCR study

Gene

Forward primer

Reverse primer

IL-1β

AACCTGCTGGTGTGTGACGTTC

CAGCACGAGGCTTTTTTGTTGT

TNF-α

CTACTCCCAGGTTCTCTTCAA

GCAGAGAGGAGGTTGACTTTC

IL-6

ACAACCACGGCCTTCCCTACTT

CACGATTTCCCAGAGAACATGTG

MCP-1

CCACTCACCTGCTGCTACTCAT

TGGTGATCCTCTTGTAGCCCTCC

Ccl5

GTCGTGTTTGTCACTCGAAGGA

TTGATGTATTCTTGAACCCACTTCTT

iNOS

CAGCTGGGCTGTACAAACCTT

CATTGGAAGTGAAGCGTTTCG

COX-2

GTGGAAAAACCTCGTCCAGA

GCTCGGCTTCCAGTATTGAG

β-Actin

AGGTCATCACTATTGGCAACGA

CACTTCATGATGGAATTGAATGTAGTT

ΔΔCt = [Cttarget - Ctβ-actin]WT or KO with arthritis - [Cttarget - Ctβ-actin]WT or KO controls

For wild-type (WT) and PARP-1 deficient samples without arthritis, ΔΔCt equals zero and 20 equals one. For wild-type and knockout (KO) samples with arthritis, the value of 2-ΔΔCt indicates the fold change in gene expression relative to the wild-type and knockout controls, respectively. Melting curves and agarose gel electrophoresis established the purity of the amplified band.

Determination of cytokines in mice arthritic knees

Knee joints were obtained, frozen in liquid nitrogen and homogenized in 0.5 ml ice-cold 20 mM Hepes buffer supplemented with 1 mM dithiothreitol, 0.1% v/v Triton and a protease inhibitor cocktail. After incubation for 30 minutes at 4°C, the homogenate was centrifuged for 10 minutes at 10,000 × g. Protein concentration was measured in supernatants by the Bradford method and a volume containing 100 μg of proteins was subjected to ELISA for IL-1β, TNF-α, IL-6 and MCP-1 (OptEIA ELISA Sets, BD Pharmingen), according to the manufacture's instructions.

Statistical analysis

Differences between experimental groups were assessed by ANCOVA, MANCOVA and Mann-Whitney U test. p values <0.05 were considered significant.

Results

PARP-1 protein expression in joint tissue

Although PARP-1 is found in the majority of the nucleated cells of the body, its expression in joint tissue has never been studied. Here, we have analyzed PARP-1 protein expression by western blot in isolated FLSs from wild-type (parp-1+/+) mice, mice lacking PARP-1 (parp-1o/o), and parp-1 heterozygous mice (parp-1+/o). PARP-1 was highly expressed in FLSs from PARP-1 wild-type mice, moderately expressed in parp-1+/o and was absent in parp-1o/o mice (Figure 1a). Comparable results were obtained in the immunohistochemical analysis of joint sections from parp-1+/+ and parp-1o/o mice with anti-PARP-1 antibody (Figure 1b, d).
Figure 1

Poly(ADP-ribose) polymerase (PARP)-1 expression in joint tissue. (a) Western blot analysis of PARP-1 and actin proteins in fibroblast-like synoviocyte extracts of the indicated genotypes; 100 ng of purified PARP-1 was the control. Immunostaining for PARP-1 expression in the knee joint sections from (b) parp-1+and (d) parp-1o/o mice. Staining for nuclear PARP-1 showed clear immunopositivity on chondrocytes from parp-1+ mice (arrows) whereas chondrocytes from parp-1o/o (arrowheads) remained negative. Negative control staining, by omitting the primary antibody, in knee joints from (c) parp-1+ and (e) parp-1o/o mice.

Reduced severity of arthritis in mice lacking PARP-1

To investigate the contribution of PARP-1 to experimental arthritis, we induced CAIA in control and PARP-1 deficient mice (Figure 2a). In eight separate experiments, male and female parp-1+/+ (n = 18), parp-1+/o (n = 8) and parp-1o/o (n = 19) mice were injected with Arthrogen and lipopolysaccharide and monitored for signs of arthritis. Evolution of arthritis was evaluated by two blinded observers on a 0 to 4 scale, as described in Materials and methods.
Figure 2

Reduced severity of arthritis in poly(ADP-ribose) polymerase (PARP)-1 deficient mice and PARP-1 sufficient mice following collagen antibody-induced arthritis induction. (a) Representative pictures of arthritis in the parp-1+ (left panels) and parp-1o/o (right panels) mice. (b) Clinical score was measured in 18 parp-1+/+, 8 parp-1+/o and 19 parp-1o/o mice from day 5 to day 12 after injection. Values are expressed as mean ± standard error of the mean; p = 0.03, parp-1+/+ and parp-1+/o versus parp-1o/o mice, by ANCOVA test.

There was no difference in incidence or clinical course of arthritis in parp-1o/o animals compared with parp-1+ control mice. The incidence of disease was 100% in control mice and 94.7% in parp-1o/o mice. In both groups, arthritis developed rapidly, the signs of disease appearing as soon as three to five days after the injection of antibody, and reached maximum severity around day seven to nine. PARP-1 deficient mice consistently displayed significantly lower severity of arthritis than parp-1+control mice (p = 0.03 by repeated measures 1-way ANCOVA test) all through the follow-up (Figure 2b).

These results suggest that PARP-1 has a role in the pathogenesis of this arthritis model.

As parp-1+/+ and parp-1+/o control mice had similar clinical phenotypes, for further analysis, they were pooled together and considered as parp-1+.

Reduced histological features of joint inflammation and cartilage damage in PARP-1 deficient mice

To quantify joint involvement, we assessed synovial inflammation in H&E stained sections of knee joints. Joints were taken from 14 parp-1o/o and 13 parp-1+ mice on days 5, 7 and 12, and histological sections were scored by two blinded observers on a 0 to 3 scale, corresponding to the degree of thickening of the synovial lining, sublining infiltration and pannus formation. On this scale, we observed a clear trend to a lower synovial inflammation score in parp-1o/o mice compared to parp-1+mice (Figures 3 and 4), although the difference was not significant (p = 0.058, by 1-way MANCOVA fixed effects test).
Figure 3

Milder synovial inflammation and cartilage damage in poly(ADP-ribose) polymerase (PARP)-1 deficient mice than in control mice. Histopathological scoring of (a) synovial inflammation and (b) cartilage damage of knee joint sections of parp-1+mice and parp-1o/o mice at day 5 and 12 after induction of collagen antibody-induced arthritis. Values are expressed as mean ± standard error of the mean; p = 0.03, parp-1+ versus parp-1o/o mice by combined analysis of (a) and (b) (MANCOVA test).

Figure 4

Representative hematoxylin-eosin stained sections of knee joints in mice with collagen antibody-induced arthritis (CAIA). Severe inflammation, pannus formation and associated cartilage destruction were observed in sections stained with hematoxylin-eosin from parp-1+ mice at (a) day 5 and (b) day 12 after CAIA induction compared to parp-1o/o mice at (c) day 5 and (d) day 12.

Joint sections were also stained with Toluidine blue, Safranin-O and Masson trichrome to evaluate cartilage damage. The results also showed a trend to less damage in parp-1o/o mice (Figures 3 and 5), although, again, the difference did not reach statistical significance (p = 0.053, by 1-way MANCOVA fixed effects test). When we considered synovial inflammation and cartilage damage jointly as two facets of the arthritic lesions, the difference between parp-1o/o and parp-1+ mice was significant (p = 0.03).
Figure 5

Representative sections stained with Safranin O in mice with collagen antibody-induced arthritis (CAIA). More severe loss of proteoglycans, indicated by destained cartilage layers, were observed in sections from parp-1+ mice at (a) day 5 and (b) day 12 after CAIA induction compared with knockout mice at (c) day 5 and (d) day 12.

Thus, PARP-1 protein appeared to be involved in the pathogenesis of the CAIA model, both in synovial inflammation and cartilage damage, although it did not seem to have a pivotal role.

It has been previously described that, in several rodent models of inflammation, PARP-1 activation is involved in neutrophil recruitment [25]. Neutrophils have been implicated in arthritis disease; specifically, extensive neutrophil exudate is displayed in CAIA model [23] and neutrophils release elastase and proteases, which degrade proteoglycans [4]. It remains possible that the decreased severity of arthritis observed in PARP-1 deficient mice was associated with reduced neutrophil exudate in joints from these mice. To evaluate this possibility, we assessed, at five and seven days, the exudate score on a 0 to 3 scale in H&E stained sections of knee joints. Exudate appeared slightly lower in parp-1o/o compared to parp-1+ mice, although the difference was not significant (p = 0.12, by 1-way MANCOVA fixed effects test) (Figure 6). Thus, lack of PARP-1 does not impair neutrophil exudation in this arthritis model.
Figure 6

Comparable exudate scores in the arthritic joints of parp-1+ and parp-1o/o mice. Exudate score was evaluated in knee sections stained with hematoxylin-eosin from parp-1+and parp-1o/o mice at day 5 and 7 after induction of collagen antibody-induced arthritis. Values represent the mean ± standard error of the mean. Differences between parp-1+and parp-1o/o mice were not statistically significant (p = 0.12 by 1-way MANCOVA test).

Expression levels of inflammatory mediators in arthritic joints from PARP-1 deficient and sufficient mice

To explore the possible mechanisms underlying the reduced arthritis observed in PARP-1 knockout mice compared to control mice, we studied, by quantitative real-time PCR, mRNA levels of IL-1β, IL-6, TNF-α, MCP-1, small inducible cytokine A5 (Cc15; RANTES), inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2 in arthritic joints at day seven after Arthrogen injection. The fold change in mRNA of arthritic versus non-arthritic parp-1o/o and parp-1+ mice is shown in Figure 7. All the inflammatory mediators were detected in both groups of mice and, interestingly, IL-1β and MCP-1 mRNA were significantly less induced in arthritic parp-1o/o compared to arthritic parp-1+ mice. IL-6 mRNA showed a trend towards lower induction in parp-1o/o compared to parp-1+ arthritic mice (p = 0.1, by Mann-Whitney U test). However, mRNA expression of TNF-α and Ccl5 were induced to a similar extend in both groups of arthritic mice (p = 0.9 and p = 0.7, respectively, by Mann-Whitney U test). Transcription of genes encoding iNOS and COX-2, which are involved in the synthesis of nitric oxide and prostaglandin E2, respectively, were induced to levels that were not significantly different in PARP-1 deficient and sufficient arthritic mice. However, a tendency towards lower induction in the parp-1o/o mice was noted.
Figure 7

Reduced IL-1β and monocyte chemotactic protein (MCP)-1 mRNA levels in mice lacking poly(ADP-ribose) polymerase (PARP)-1. IL-1β, MCP-1, inducible nitric oxide synthase (iNOS), cyclooxygenase (COX)-2, tumor necrosis factor (TNF)-α, IL-6 and small inducible cytokine A5 (Ccl5) mRNA levels were measured by quantitative real-time PCR in arthritic joints of parp-1+ and parp-1o/o mice at day 7 after induction of collagen antibody-induced arthritis. Values are expressed as mean ± standard error of the mean of six to nine mice per group. Differences between parp-1+ and parp-1o/o mice were statistically significant for IL-1β (asterisk indicates p = 0.005) and MCP-1 (asterisk indicates p = 0.004) by Mann-Whitney U test.

To confirm these findings, we next determined the levels of IL-1β, IL-6, TNF-α and MCP-1 proteins in joint tissues. IL-1β and MCP-1 were significantly reduced in joints from arthritic parp-1o/o compared to arthritic parp-1+ mice (Figure 8); however, there was no difference in the production of TNF-α and IL-6 in both groups of mice (p = 0.4 and p = 0.3, respectively, by Mann-Whitney U test). These results are consistent with those obtained for the mRNA analysis.
Figure 8

Reduced IL-1β and monocyte chemotactic protein (MCP)-1 levels in arthritic joints of mice lacking poly(ADP-ribose) polymerase (PARP)-1. Levels of IL-1β, tumor necrosis factor (TNF)-α, IL-6 and MCP-1 were measured by ELISA in extracts from arthritic knee joints of mice at day 7 after induction of collagen antibody-induced arthritis. Values are expressed as mean ± standard error of the mean of six to nine mice per group. Differences between parp-1+ and parp-1o/o mice were statistically significant for IL-1β (asterisk indicates p = 0.03) and MCP-1 (asterisk indicates p = 0.05) by Mann-Whitney U test.

Discussion

Previous studies using genetically engineered animals and pharmacological inhibitors have implicated PARP-1 in the pathogenesis of several inflammatory processes [1316]. In the present report, we have investigated the impact of selective PARP-1 suppression in the CAIA model and found that absence of PARP-1 protein reduces the severity of disease, likely by the impairment of IL-1β and MCP-1 transcription in joint tissues. In the arthritis model used, disease develops in most mice strains, avoiding multiple breeding into arthritis susceptible strains. Using a suitable antibody dose, arthritis incidence rises to 100% in control animals and the clinical severity and histopathology are similar to collagen-induced arthritis and human RA. Given the involvement of PARP-1 in inflammation, we considered that it could have a role in the effector phase of arthritis; the CAIA model specifically reflects this phase.

PARP-1 deficient mice had decreased severity in clinical and histological arthritis, although the incidence of disease was similar in control and deficient mice. This is in line with its described involvement in other inflammatory diseases, but with milder effect in the case of arthritis.

PARP-1 belongs to a large family of 18 proteins, encoded by different genes and displaying a conserved catalytic domain (for reviews, see [26, 27]). PARP-1 catalyzes 80% of cellular poly(ADPribosyl)ation and the other PARP family members, PARP-2, PARP-3, PARP-4 and Tankyrases (PARP-5 a and b), all identified in the last few years, account for the remaining 20%. Therefore, it is possible that when PARP-1 is absent from development, other PARP family members with poly(ADPribosyl)ation activity could compensate for its absence. To evaluate this possibility, we treated parp-1o/o and parp-1+ mice with 3,4-dihydro-5- [4-(1-piperidinyl)butoxy]-1(2H)-isoquinolinone (DPQ), one of the new potent PARP inhibitors developed. After treatment, we found similar protection to that observed in mice lacking the parp-1 gene (data not shown), suggesting that PARP-1 is the member of the PARP proteins involved in arthritis inflammation.

Our results contrast with the significantly reduced incidence and severity of collagen induced arthritis in mice treated with INH2BP, a PARP inhibitor, reported by Szabo and colleagues [28]. It is possible that INH2BP has effects other than the inhibition of PARP function, because we did not observe such a strong effect with knockout mice, nor with the DPQ inhibitor. Nevertheless, this discordance could also be attributed to either differences in the arthritis model or differences in the inhibitors. In fact, it has been recently shown that another PARP inhibitor, PJ34, reduces the severity rather than incidence of collagen induced arthritis [16].

IL-1β is one of the major cytokines in arthritis driving inflammation and joint destruction [2, 4, 7]. It has been reported that systemic administration of IL-1 accelerates and exacerbates the development of murine collagen induced arthritis [29], while IL-1 receptor antagonist-deficient mice (BALB/c background) develop chronic polyarthropathy resembling RA [30]. MCP-1 is a potent chemoattractant for monocytes. It seems to be involved in RA pathogenesis because it has been detected in patient sera and found at increased levels in FLSs from RA patients [3133]. It has been recently reported that MCP-1 induces FLS proliferation, which is pivotal in pannus formation, and increases metalloproteinase production mediated by IL-1β [34].

Thus, the strong reduction in IL-1β and MCP-1 production observed in PARP-1 deficient mice may account for the reduced severity of arthritis, though signals of a more widespread effect are reflected in the tendency towards the decreased expression of other inflammatory mediators, such as IL-6, iNOS and COX-2.

In contrast to what has been described in the shock endotoxic model [13, 16], we did not find impaired TNF-α production in mice lacking PARP-1. This could indicate that the requirements of PARP-1 for transcription of inflammatory genes depend on the tissue and the nature of the inflammatory stimulus. In fact, studies with a PARP inhibitor have shown an inhibitory or neutral effect on IL-1β levels depending on the model of inflammation [16].

Conclusion

Overall, our results indicate that PARP-1 plays a role in arthritis progression, probably through impaired IL-1β and MCP-1 production in joints. Although further investigations are required to evaluate PARP-1 involvement in human RA, this enzyme might be considered as a new target for experimental treatment.

Abbreviations

CAIA: 

collagen antibody-induced arthritis

Ccl5 (RANTES): 

small inducible cytokine A5

COX-2: 

cyclooxygenase

DMEM: 

Dulbecco's modified Eagle's medium

DPQ: 

3,4-dihydro-5- [4-(1-piperidinyl)butoxy]-1(2H)-isoquinolinone

FLS: 

fibroblast-like synoviocyte

H&E: 

hematoxylin and eosin

IL: 

interleukin

iNOS: 

inducible nitric oxide synthase

MCP: 

monocyte chemotactic protein

NF: 

nuclear factor

PARP: 

poly(ADP-ribose) polymerase

RA: 

rheumatoid arthritis

TNF: 

tumor necrosis factor.

Declarations

Acknowledgements

We thank Dr G de Murcia and Dr J Ménissier de Murcia for critical review of this manuscript and for providing the PARP-1 deficient mice and anti-PARP-1 antibody (VIC-5). Supported by Fondo de Investigación Sanitaria (FIS), Instituto de Salud Carlos III (Spain), grants 01/3054, 02/0490 and G03/152 and by grants from DXID (Xunta de Galicia). AB is supported by FIS (02/0490) and CC is recipient of a research contract from FIS (01/3054) and Servicio Gallego de Salud (SERGAS).

Authors’ Affiliations

(1)
Research Laboratory, Hospital Clínico Universitario
(2)
Department of Pathology, Hospital Clínico Universitario
(3)
Rheumatology Unit, Hospital Clínico Universitario and Department of Medicine, Universidad de Santiago

References

  1. Feldmann M, Brennan FM, Maini RN: Rheumatoid arthritis. Cell. 1996, 85: 307-310. 10.1016/S0092-8674(00)81109-5.View ArticlePubMedGoogle Scholar
  2. Firestein GS: Evolving concepts of rheumatoid arthritis. Nature. 2003, 423: 356-361. 10.1038/nature01661.View ArticlePubMedGoogle Scholar
  3. Loetscher P, Moser B: Homing chemokines in rheumatoid arthritis. Arthritis Res. 2002, 4: 233-236. 10.1186/ar412.PubMed CentralView ArticlePubMedGoogle Scholar
  4. Choy EH, Panayi GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001, 344: 907-916. 10.1056/NEJM200103223441207.View ArticlePubMedGoogle Scholar
  5. Sweeney SE, Firestein GS: Rheumatoid arthritis: regulation of synovial inflammation. Int J Biochem Cell Biol. 2004, 36: 372-378. 10.1016/S1357-2725(03)00259-0.View ArticlePubMedGoogle Scholar
  6. Wong PK, Campbell IK, Egan PJ, Ernst M, Wicks IP: The role of the interleukin-6 family of cytokines in inflammatory arthritis and bone turnover. Arthritis Rheum. 2003, 48: 1177-1189. 10.1002/art.10943.View ArticlePubMedGoogle Scholar
  7. Feldmann M, Brennan FM, Foxwell BM, Maini RN: The role of TNF alpha and IL-1 in rheumatoid arthritis. Curr Dir Autoimmun. 2001, 3: 188-199.View ArticlePubMedGoogle Scholar
  8. Miossec P: An update on the cytokine network in rheumatoid arthritis. Curr Opin Rheumatol. 2004, 16: 218-222. 10.1097/00002281-200405000-00009.View ArticlePubMedGoogle Scholar
  9. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, et al: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997, 337: 141-147. 10.1056/NEJM199707173370301.View ArticlePubMedGoogle Scholar
  10. Gabay C, Arend WP: Treatment of rheumatoid arthritis with IL-1 inhibitors. Springer Semin Immunopathol. 1998, 20: 229-246.View ArticlePubMedGoogle Scholar
  11. de Murcia G, Ménissier-de Murcia J: Poly(ADP-ribose) polymerase: a molecular nick-sensor. Trends Biochem Sci. 1994, 19: 172-176. 10.1016/0968-0004(94)90280-1.View ArticlePubMedGoogle Scholar
  12. Shall S, de Murcia G: Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model?. Mutation Res. 2000, 460: 1-15.View ArticlePubMedGoogle Scholar
  13. Oliver FJ, Ménissier-de Murcia J, Nacci C, Decker P, Andriantsitohaina R, Muller S, de la Rubia G, Stoclet JC, de Murcia G: Resistance to endotoxic shock as a consequence of defective NF-κB activation in poly(ADP-ribose) polymerase-1 deficient mice. EMBO J. 1999, 18: 4446-4454. 10.1093/emboj/18.16.4446.PubMed CentralView ArticlePubMedGoogle Scholar
  14. Burkat V, Wang ZQ, Radons J, Heller B, Herceg Z, Stingl L, Wagner EF, Kolb H: Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic β-cell destruction and diabetes development induced by streptozocin. Nature Med. 1999, 5: 314-319. 10.1038/6535.View ArticleGoogle Scholar
  15. Zingarelli B, Szabo C, Salzman AL: Blockade of Poly(ADP-ribose) synthetase inhibits neutrophil recruitment, oxidant generation, and mucosal injury in murine colitis. Gastroenterology. 1999, 116: 335-345. 10.1016/S0016-5085(99)70130-7.View ArticlePubMedGoogle Scholar
  16. Mabley JG, Jagtap P, Perretti M, Getting SJ, Salzman AL, Virág L, Szabó E, Soriano FJ, Liaudet L, Abdelkarim GE, et al: Anti-inflammatory effects of a novel, potent inhibitor of poly(ADP-ribose) polymerase. Inflamm Res. 2001, 50: 561-569. 10.1007/PL00000234.View ArticlePubMedGoogle Scholar
  17. Szabó C, Dawson V: Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion. Trends Pharmacol Sci. 1998, 19: 287-298. 10.1016/S0165-6147(98)01193-6.View ArticlePubMedGoogle Scholar
  18. Chang W-J, Alvarez-Gonzalez R: The sequence-specific DNA binding of NF-κB is reversibly regulated by the automodification reaction of poly (ADP-ribose) polymerase 1. J Biol Chem. 2001, 276: 47664-47670. 10.1074/jbc.M104666200.View ArticlePubMedGoogle Scholar
  19. Hassa PO, Hottiger MO: A role of poly(ADP-ribose) polymerase in NF-κB transcriptional activation. Biol Chem. 1999, 380: 953-959. 10.1515/BC.1999.118.View ArticlePubMedGoogle Scholar
  20. Ha HC, Hester LD, Snyder SH: Poly(ADP-ribose) polymerase-1 dependence of stress-induced transcription factors and associated gene expression in glia. Proc Natl Acad Sci USA. 2002, 99: 3270-3275. 10.1073/pnas.052712399.PubMed CentralView ArticlePubMedGoogle Scholar
  21. Andreone TL, O'Connor M, Denenberg A, Hake PW, Zingarelli B: Poly(ADP-ribose) polymerase-1 regulates activation of activator protein-1 in murine fibroblasts. J Immunol. 2003, 170: 2113-2120.View ArticlePubMedGoogle Scholar
  22. de Murcia JM, Niedergan C, Trucco C, Ricoul M, Dutrillaux B, Mark M, Oliver FJ, Masson M, Dierich A, LeMeur M, et al: Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci USA. 1997, 94: 7303-7307. 10.1073/pnas.94.14.7303.PubMed CentralView ArticlePubMedGoogle Scholar
  23. Terato K, Hasty KA, Reife RA, Cremer MA, Kang AH, Stuart JM: Induction of arthritis with monoclonal antibodies to collagen. J Immunol. 1992, 148: 2103-2108.PubMedGoogle Scholar
  24. Conde C, Mark M, Oliver FJ, Huber A, de Murcia G, Ménissier-de Murcia J: Loss of poly(ADP-ribose) polymerase-1 causes increased tumour latency in p53-deficient mice. EMBO J. 2001, 20: 3535-3543. 10.1093/emboj/20.13.3535.PubMed CentralView ArticlePubMedGoogle Scholar
  25. Szabo C, Lim LH, Cuzzocrea S, Getting SJ, Zingarelli B, Flower RJ, Salzman AL, Perretti M: Inhibition of poly (ADP-ribose) synthetase attenuates neutrophil recruitment and exerts antiinflammatory effects. J Exp Med. 1997, 186: 1041-1049. 10.1084/jem.186.7.1041.PubMed CentralView ArticlePubMedGoogle Scholar
  26. Amé JC, Spenlehauer C, de Murcia G: The PARP superfamily. BioEssays. 2004, 26: 882-893. 10.1002/bies.20085.View ArticlePubMedGoogle Scholar
  27. Bürkle A: Physiology and pathophysiology of poly(ADP-ribosyl)ation. BioEssays. 2001, 23: 795-806. 10.1002/bies.1115.View ArticlePubMedGoogle Scholar
  28. Szabo C, Virág L, Cuzzocrea S, Scott GS, Hake P, O'Connor MP, Zingarelli B, Salzman A, Kun E: Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase. Proc Natl Acad Sci USA. 1998, 95: 3867-3872. 10.1073/pnas.95.7.3867.PubMed CentralView ArticlePubMedGoogle Scholar
  29. Hom JT, Bendele AM, Carlson DG: In vivo administration with IL-1 accelerates the development of collagen-induced arthritis in mice. J Immunol. 1998, 141: 834-841.Google Scholar
  30. Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, Ikuse T, Asano M, Iwakura Y: Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med. 2000, 191: 313-320. 10.1084/jem.191.2.313.PubMed CentralView ArticlePubMedGoogle Scholar
  31. Koch AE, Kunkel SL, Harlow LA, Johnson B, Evanoff HL, Haines GK, Burdick MD, Pope RM, Strieter RM: Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest. 1992, 90: 772-779.PubMed CentralView ArticlePubMedGoogle Scholar
  32. Villiger PM, Terkeltaub R, Lotz M: Production of monocyte chemoattractant protein-1 by inflamed synovial tissue and cultured synoviocytes. J Immunol. 1992, 149: 722-727.PubMedGoogle Scholar
  33. Harigai M, Hara M, Yoshimura T, Leonard EJ, Inoue K, Kashiwazaki S: Monocyte chemoattractant protein-1 (MCP-1) in inflammatory joint diseases and its involvement in the cytokine network of rheumatoid synovium. Clin Immunol Immunopathol. 1993, 69: 83-91. 10.1006/clin.1993.1153.View ArticlePubMedGoogle Scholar
  34. García-Vicuña R, Gómez-Gaviro MV, Domínguez-Luis MJ, Pec MK, González-Alvaro I, Alvaro-Gracia JM, Díaz-González F: CC and CXC chemokine receptors mediate migration, proliferation, and matrix metalloproteinase production by fibroblast-like synoviocytes from rheumatoid arthritis patients. Arthritis Rheum. 2004, 50: 3866-3877. 10.1002/art.20615.View ArticlePubMedGoogle Scholar

Copyright

© García et al.; licensee BioMed Central Ltd. 2005

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.